The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.

Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.

Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.

What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.

Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.

Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.

The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.